Positive results pertaining to RC48 Phase II clinical trials were announced by RemeGen Ltd. The company had evaluated a potential new medicine for patients who have HER2-positive metastatic or unresectable urothelial cancer. These patients had undergone chemotherapy treatment earlier and had visceral metastasis.
51 percent confirmed objective response rate per independent central review was obtained from the results. Hemotoxicity, alopecia and hypothesia are the adverse events associated with common treatment.
RC-48 is a novel antibody-drug conjugate developed for the treatment of HER2-positive solid tumors. It includes a cathepsin cleavable linker, HER2-monoclonal antibody and monomethyl auristatin E as cytotoxic payload. It has an excellent safety profile as depicted in clinical trials. RC48 could be able to support patients whose cancer has progressed following the standard chemotherapy treatment and immune-oncology agents.
Urothelial carcinoma is a widespread cancer and RC48 is believed to be an efficient treatment for the patients. In spite of being a common form of bladder cancer, there is no breakthrough treatment for the disease so far. Cisplatin-based chemotherapy is the current therapeutic option which has high recurrence and mortality rate.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like